Jennifer L Whitwell

List of Publications by Year in Descending Order

235 papers	15,126 citations	58 h-index	119 g-index
268 ext. papers	17,880 ext. citations	5.8 avg, IF	6.2 L-index

#	Paper	IF	Citations
235	TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration.. *NeuroImage: Clinical*, **2022**, 34, 102954	5.3	0
234	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition.. *Acta Neuropathologica Communications*, **2022**, 10, 16	7.3	1
233	Tractography of supplementary motor area projections in progressive speech apraxia and aphasia.. *NeuroImage: Clinical*, **2022**, 34, 102999	5.3	1
232	Depression and Apathy across Different Variants of Progressive Supranuclear Palsy.. *Movement Disorders Clinical Practice*, **2022**, 9, 212-217	2.2	0
231	Cross-Sectional and Longitudinal Assessment of Behavior in Primary Progressive Apraxia of Speech and Agrammatic Aphasia.. *Dementia and Geriatric Cognitive Disorders*, **2022**, 1-10	2.6	
230	Diffusion tractography of Superior Cerebellar Peduncle and Dentatorubrothalamic Tracts in two Autopsy Confirmed Progressive Supranuclear Palsy Variants: Richardson syndrome and the speech-language variant. *NeuroImage: Clinical*, **2022**, 103030	5.3	0
229	In Vivo Imaging and Autoradiography in a Case of Autopsy-Confirmed Pick Disease. *Neurology: Clinical Practice*, **2021**, 11, e11-e14	1.7	4
228	Survival Analysis in Primary Progressive Apraxia of Speech and Agrammatic Aphasia. *Neurology: Clinical Practice*, **2021**, 11, 249-255	1.7	3
227	Dynamic Aphasia as a Variant of Frontotemporal Dementia. *Cognitive and Behavioral Neurology*, **2021**, 34, 303-318	1.6	0
226	Neuroimaging correlates of gait abnormalities in progressive supranuclear palsy. *NeuroImage: Clinical*, **2021**, 32, 102850	5.3	1
225	Autopsy Validation of Progressive Supranuclear Palsy-Predominant Speech/Language Disorder Criteria. *Movement Disorders*, **2021**,	7	2
224	Diffusion tensor imaging analysis in three progressive supranuclear palsy variants. *Journal of Neurology*, **2021**, 268, 3409-3420	5.5	8
223	TAR DNA-Binding Protein 43 Is Associated with Rate of Memory, Functional and Global Cognitive Decline in the Decade Prior to Death. *Journal of Alzheimer's Disease*, **2021**, 80, 683-693	4.3	2
222	Update on neuroimaging in Alzheimer's disease. *Current Opinion in Neurology*, **2021**, 34, 525-531	7.1	2
221	Old age genetically confirmed frontotemporal lobar degeneration with TDP-43 has limbic predominant TDP-43 deposition. *Neuropathology and Applied Neurobiology*, **2021**, 47, 1050-1059	5.2	3
220	Progressive apraxia of speech: delays to diagnosis and rates of alternative diagnoses. *Journal of Neurology*, **2021**, 268, 4752-4758	5.5	2
219	Clinical, Imaging, and Pathologic Characteristics of Patients With Right vs Left Hemisphere-Predominant Logopenic Progressive Aphasia. *Neurology*, **2021**, 97, e523-e534	6.5	1

218	A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech. *Nature Communications*, **2021**, 12, 3452	17.4	10
217	Neurodegeneration of the visual word form area in a patient with word form alexia. *Neurology and Clinical Neuroscience*, **2021**, 9, 359-360	0.3	0
216	Motor Speech Disorders and Communication Limitations in Progressive Supranuclear Palsy. *American Journal of Speech-Language Pathology*, **2021**, 30, 1361-1372	3.1	5
215	Neuropsychological Profiles of Patients with Progressive Apraxia of Speech and Aphasia. *Journal of the International Neuropsychological Society*, **2021**, 1-11	3.1	
214	Tau and Amyloid Relationships with Resting-state Functional Connectivity in Atypical Alzheimer's Disease. *Cerebral Cortex*, **2021**, 31, 1693-1706	5.1	13
213	Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia Phenotype. *Annals of Neurology*, **2021**, 89, 520-533	9.4	6
212	Neurobehavioral Characteristics of FDG-PET Defined Right-Dominant Semantic Dementia: A Longitudinal Study. *Dementia and Geriatric Cognitive Disorders*, **2021**, 50, 17-28	2.6	0
211	Phonological Errors in Posterior Cortical Atrophy. *Dementia and Geriatric Cognitive Disorders*, **2021**, 50, 195-203	2.6	1
210	A Longitudinal Evaluation of Speech Rate in Primary Progressive Apraxia of Speech. *Journal of Speech, Language, and Hearing Research*, **2021**, 64, 392-404	2.8	5
209	Underlying pathology identified after 20 years of disease course in two cases of slowly progressive frontotemporal dementia syndromes. *Neurocase*, **2021**, 27, 212-222	0.8	1
208	Gray and White Matter Correlates of Dysphagia in Progressive Supranuclear Palsy. *Movement Disorders*, **2021**, 36, 2669-2675	7	2
207	Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies. *Nature Reviews Neurology*, **2021**, 17, 601-620	15	5
206	Posterior cortical atrophy phenotypic heterogeneity revealed by decoding F-FDG-PET. *Brain Communications*, **2021**, 3, fcab182	4.5	3
205	Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease. *Neurology*, **2021**, 97, 908-909	6.5	3
204	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. *NeuroImage*, **2021**, 238, 118259	7.9	4
203	Laboratory based assessment of gait and balance impairment in patients with progressive supranuclear palsy. *Journal of the Neurological Sciences*, **2021**, 429, 118054	3.2	1
202	Sleep disturbances in the speech-language variant of progressive supranuclear palsy. *Parkinsonism and Related Disorders*, **2021**, 91, 9-12	3.6	0
201	Relationship of APOE, age at onset, amyloid and clinical phenotype in Alzheimer disease. *Neurobiology of Aging*, **2021**, 108, 90-98	5.6	1

200	Brainstem Biomarkers of Clinical Variant and Pathology in Progressive Supranuclear Palsy.. *Movement Disorders*, **2021**,	7	2
199	Protein contributions to brain atrophy acceleration in Alzheimer's disease and primary age-related tauopathy. *Brain*, **2020**, 143, 3463-3476	11.2	13
198	Ioflupane 123I (DAT scan) SPECT identifies dopamine receptor dysfunction early in the disease course in progressive apraxia of speech. *Journal of Neurology*, **2020**, 267, 2603-2611	5.5	6
197	Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. *Neurology*, **2020**, 95, e23-e34	6.5	11
196	Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes. *Brain*, **2020**, 143, 2281-2294	11.2	23
195	Longitudinal flortaucipir ([F]AV-1451) PET uptake in semantic dementia. *Neurobiology of Aging*, **2020**, 92, 135-140	5.6	2
194	Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants. *NeuroImage: Clinical*, **2020**, 25, 102152	5.3	20
193	Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimer's Disease Neuropathological Changes. *Journal of Alzheimer's Disease*, **2020**, 73, 1511-1523	4.3	5
192	TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease. *Journal of Neurology*, **2020**, 267, 1444-1453	5.5	1
191	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. *Annals of Clinical and Translational Neurology*, **2020**, 7, 707-721	5.3	6
190	Longitudinal anatomic, functional, and molecular characterization of Pick disease phenotypes. *Neurology*, **2020**, 95, e3190-e3202	6.5	4
189	Western Aphasia Battery-Revised Profiles in Primary Progressive Aphasia and Primary Progressive Apraxia of Speech. *American Journal of Speech-Language Pathology*, **2020**, 29, 498-510	3.1	11
188	Communication Limitations in Patients With Progressive Apraxia of Speech and Aphasia. *American Journal of Speech-Language Pathology*, **2020**, 29, 1976-1986	3.1	9
187	Dysphagia in Progressive Supranuclear Palsy. *Dysphagia*, **2020**, 35, 667-676	3.7	12
186	Longitudinal flortaucipir ([F]AV-1451) PET imaging in primary progressive apraxia of speech. *Cortex*, **2020**, 124, 33-43	3.8	3
185	The evolution of parkinsonism in primary progressive apraxia of speech: A 6-year longitudinal study. *Parkinsonism and Related Disorders*, **2020**, 81, 34-40	3.6	9
184	Predicting future rates of tau accumulation on PET. *Brain*, **2020**, 143, 3136-3150	11.2	25
183	Dementia with Lewy bodies presenting as Logopenic variant primary progressive Aphasia. *Neurocase*, **2020**, 26, 259-263	0.8	4

182	Longitudinal Amyloid-PET in Atypical Alzheimer's Disease and Frontotemporal Lobar Degeneration. *Journal of Alzheimer's Disease*, **2020**, 74, 377-389	4.3	5
181	Automated Hippocampal Subfield Volumetric Analyses in Atypical Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2020**, 78, 927-937	4.3	2
180	Sensitivity-Specificity of Tau and Amyloid Positron Emission Tomography in Frontotemporal Lobar Degeneration. *Annals of Neurology*, **2020**, 88, 1009-1022	9.4	9
179	Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies. *Movement Disorders*, **2020**, 35, 171-176	7	23
178	Neuroanatomical correlates of phonologic errors in logopenic progressive aphasia. *Brain and Language*, **2020**, 204, 104773	2.9	7
177	Association between transactive response DNA-binding protein of 43 kDa type and cognitive resilience to Alzheimer's disease: a case-control study. *Neurobiology of Aging*, **2020**, 92, 92-97	5.6	4
176	Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. *Brain*, **2019**, 142, 3621-3635	11.2	22
175	The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals. *Neurobiology of Aging*, **2019**, 77, 26-36	5.6	32
174	Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome. *Brain*, **2019**, 142, 2466-2482	11.2	18
173	An Evaluation of the Progressive Supranuclear Palsy Speech/Language Variant. *Movement Disorders Clinical Practice*, **2019**, 6, 452-461	2.2	20
172	Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease. *NeuroImage: Clinical*, **2019**, 23, 101823	5.3	27
171	Brain atrophy in primary age-related tauopathy is linked to transactive response DNA-binding protein of 43 kDa. *Alzheimer's and Dementia*, **2019**, 15, 799-806	1.2	11
170	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. *Movement Disorders*, **2019**, 34, 1228-1232	7	56
169	Atrophy in midbrain & cerebral/cerebellar pedunculi is characteristic for progressive supranuclear palsy - A double-validation whole-brain meta-analysis. *NeuroImage: Clinical*, **2019**, 22, 101722	5.3	11
168	The role of age on tau PET uptake and gray matter atrophy in atypical Alzheimer's disease. *Alzheimer's and Dementia*, **2019**, 15, 675-685	1.2	18
167	Prominent auditory deficits in primary progressive aphasia: A case study. *Cortex*, **2019**, 117, 396-406	3.8	7
166	Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy. *Movement Disorders*, **2019**, 34, 1144-1153	7	56
165	Clinical and neuroimaging characteristics of clinically unclassifiable primary progressive aphasia. *Brain and Language*, **2019**, 197, 104676	2.9	21

164	LATE to the PART-y. *Brain*, **2019**, 142, e47	11.2	25
163	Multimodal neuroimaging relationships in progressive supranuclear palsy. *Parkinsonism and Related Disorders*, **2019**, 66, 56-61	3.6	10
162	FTD spectrum: Neuroimaging across the FTD spectrum. *Progress in Molecular Biology and Translational Science*, **2019**, 165, 187-223	4	10
161	Corticobasal degeneration. *International Review of Neurobiology*, **2019**, 149, 87-136	4.4	12
160	Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. *Acta Neuropathologica*, **2019**, 137, 227-238	14.3	32
159	MRI Outperforms [18F]AV-1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy. *Movement Disorders*, **2019**, 34, 105-113	7	21
158	F-AV-1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy. *Movement Disorders*, **2019**, 34, 344-352	7	18
157	The influence of □amyloid on [F]AV-1451 in semantic variant of primary progressive aphasia. *Neurology*, **2019**, 92, e710-e722	6.5	8
156	Electroencephalography in Primary Progressive Aphasia and Apraxia of Speech. *Aphasiology*, **2019**, 33, 1410-1417	1.6	4
155	Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer's disease. *Human Brain Mapping*, **2019**, 40, 1618-1631	5.9	26
154	Regional Distribution, Asymmetry, and Clinical Correlates of Tau Uptake on [18F]AV-1451 PET in Atypical Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2018**, 62, 1713-1724	4.3	32
153	[F]AV-1451 tau-PET and primary progressive aphasia. *Annals of Neurology*, **2018**, 83, 599-611	9.4	46
152	Multimodal neuroimaging provides insights into the biology of Alzheimer's disease. *Brain*, **2018**, 141, 326-329	11.2	2
151	Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech. *Cortex*, **2018**, 99, 358-374	3.8	31
150	Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy. *Parkinsonism and Related Disorders*, **2018**, 48, 3-9	3.6	22
149	[F]AV-1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. *Annals of Neurology*, **2018**, 83, 248-257	9.4	42
148	Longitudinal structural and molecular neuroimaging in agrammatic primary progressive aphasia. *Brain*, **2018**, 141, 302-317	11.2	23
147	Tau Imaging in Parkinsonism: What Have We Learned So Far?. *Movement Disorders Clinical Practice*, **2018**, 5, 118-130	2.2	9

146	Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease. *Alzheimer's and Dementia*, **2018**, 14, 1005-1014	1.2	47
145	Disrupted functional connectivity in primary progressive apraxia of speech. *NeuroImage: Clinical*, **2018**, 18, 617-629	5.3	19
144	Molecular neuroimaging in primary progressive aphasia with predominant agraphia. *Neurocase*, **2018**, 24, 121-123	0.8	0
143	Prosodic and phonetic subtypes of primary progressive apraxia of speech. *Brain and Language*, **2018**, 184, 54-65	2.9	62
142	TDP-43 and Alzheimer's Disease Pathologic Subtype in Non-Amnestic Alzheimer's Disease Dementia. *Journal of Alzheimer's Disease*, **2018**, 64, 1227-1233	4.3	16
141	Non-right handed primary progressive apraxia of speech. *Journal of the Neurological Sciences*, **2018**, 390, 246-254	3.2	4
140	Quantitative Analysis of Agrammatism in Agrammatic Primary Progressive Aphasia and Dominant Apraxia of Speech. *Journal of Speech, Language, and Hearing Research*, **2018**, 61, 2337-2346	2.8	10
139	Clinical and imaging progression over 10 years in a patient with primary progressive apraxia of speech and autopsy-confirmed corticobasal degeneration. *Neurocase*, **2018**, 24, 111-120	0.8	18
138	IC-P-083: DIAGNOSTIC UTILITY OF [18F]AV-1451 PET, FDG-PET AND MRI TO DIFFERENTIATE THE THREE VARIANTS OF PRIMARY PROGRESSIVE APHASIA **2018**, 14, P71-P72		
137	IC-02-05: THE INFLUENCE OF AGE ON REGIONAL [18F]AV-1451 PET, PITTSBURGH COMPOUND B PET AND MRI ATROPHY IN ATYPICAL ALZHEIMER'S DISEASE **2018**, 14, P6-P7		
136	Rapid rate on quasi-speech tasks in the semantic variant of primary progressive aphasia: A non-motor phenomenon?. *Journal of the Acoustical Society of America*, **2018**, 144, 3364	2.2	1
135	Clinical Progression in Four Cases of Primary Progressive Apraxia of Speech. *American Journal of Speech-Language Pathology*, **2018**, 27, 1303-1318	3.1	23
134	Association of Apolipoprotein E ε4 With Transactive Response DNA-Binding Protein 43. *JAMA Neurology*, **2018**, 75, 1347-1354	17.2	42
133	Patterns of Neuropsychological Dysfunction and Cortical Volume Changes in Logopenic Aphasia. *Journal of Alzheimer's Disease*, **2018**, 66, 1015-1025	4.3	12
132	Quantitative assessment of grammar in amyloid-negative logopenic aphasia. *Brain and Language*, **2018**, 186, 26-31	2.9	2
131	Alzheimer's disease neuroimaging. *Current Opinion in Neurology*, **2018**, 31, 396-404	7.1	11
130	Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). *Acta Neuropathologica*, **2017**, 133, 705-715	14.3	91
129	Temporal acoustic measures distinguish primary progressive apraxia of speech from primary progressive aphasia. *Brain and Language*, **2017**, 168, 84-94	2.9	38

128	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. *Movement Disorders*, **2017**, 32, 995-1005	7	88
127	Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. *Movement Disorders*, **2017**, 32, 955-971	7	127
126	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. *Movement Disorders*, **2017**, 32, 853-864	7	840
125	Brain tau deposition linked to systemic causes of death in normal elderly. *Neurobiology of Aging*, **2017**, 50, 163-166	5.6	2
124	Predicting clinical decline in progressive agrammatic aphasia and apraxia of speech. *Neurology*, **2017**, 89, 2271-2279	6.5	18
123	Uptake of AV-1451 in meningiomas. *Annals of Nuclear Medicine*, **2017**, 31, 736-743	2.5	4
122	Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study. *Lancet Neurology, The*, **2017**, 16, 917-924	24.1	101
121	[F]AV-1451 tau positron emission tomography in progressive supranuclear palsy. *Movement Disorders*, **2017**, 32, 124-133	7	105
120	F-FDG PET in Posterior Cortical Atrophy and Dementia with Lewy Bodies. *Journal of Nuclear Medicine*, **2017**, 58, 632-638	8.9	60
119	Tracking the development of agrammatic aphasia: A tensor-based morphometry study. *Cortex*, **2017**, 90, 138-148	3.8	17
118	[IC-P-204]: SUBJECT-LEVEL ASSESSMENT OF REGIONAL CORRELATIONS BETWEEN TAU-PET, AMYLOID-PET, MRI AND FDG-PET ACROSS THE CLINICAL SPECTRUM OF ALZHEIMER's DISEASE **2017**, 13, P149		
117	[O1□06□05]: SUBJECT-LEVEL ASSESSMENT OF REGIONAL CORRELATIONS BETWEEN TAU-PET, AMYLOID-PET, MRI AND FDG-PET ACROSS THE CLINICAL SPECTRUM OF ALZHEIMER's DISEASE **2017**, 13, P203		
116	Varying Degrees of Temporoparietal Hypometabolism on FDG-PET Reveal Amyloid-Positive Logopenic Primary Progressive Aphasia is not a□Homogeneous Clinical Entity. *Journal of Alzheimer's Disease*, **2017**, 55, 1019-1029	4.3	19
115	[18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. *Acta Neuropathologica*, **2016**, 132, 931-933	14.3	98
114	Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy. *Parkinsonism and Related Disorders*, **2016**, 28, 29-35	3.6	13
113	Coprophagia in neurologic disorders. *Journal of Neurology*, **2016**, 263, 1008-1014	5.5	12
112	Updated TDP-43 in Alzheimer's disease staging scheme. *Acta Neuropathologica*, **2016**, 131, 571-85	14.3	168
111	Clinical and MRI models predicting amyloid deposition in progressive aphasia and apraxia of speech. *NeuroImage: Clinical*, **2016**, 11, 90-98	5.3	8

110	Uncovering Neuroanatomical Networks Responsible for Abnormal Eating Behavior in Frontotemporal Dementia. *JAMA Neurology*, **2016**, 73, 267-8	17.2	1
109	Mixed tau and TDP-43 pathology in a patient with unclassifiable primary progressive aphasia. *Neurocase*, **2016**, 22, 55-9	0.8	8
108	Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimer's Disease: A Diffusion Tensor Imaging Study. *Journal of Alzheimer's Disease*, **2016**, 49, 633-43	4.3	18
107	IC-P-201: Predicting Amyloid Deposition in Progressive Aphasia and Apraxia of Speech Using Clinical and Mri Data **2016**, 12, P144-P145		
106	IC-P-203: AV-1451 TAU-PET Binding in Typical and Atypical Syndromic Variants of Alzheimer's Disease **2016**, 12, P145-P145		
105	Working memory and language network dysfunctions in logopenic aphasia: a task-free fMRI comparison with Alzheimer's dementia. *Neurobiology of Aging*, **2015**, 36, 1245-52	5.6	64
104	Classification and clinicoradiologic features of primary progressive aphasia (PPA) and apraxia of speech. *Cortex*, **2015**, 69, 220-36	3.8	99
103	Sample size calculations for clinical trials targeting tauopathies: a new potential disease target. *Journal of Neurology*, **2015**, 262, 2064-72	5.5	7
102	Primary progressive apraxia of speech: clinical features and acoustic and neurologic correlates. *American Journal of Speech-Language Pathology*, **2015**, 24, 88-100	3.1	52
101	Neuropsychiatric symptoms in primary progressive aphasia and apraxia of speech. *Dementia and Geriatric Cognitive Disorders*, **2015**, 39, 228-38	2.6	27
100	Clinical, FDG and amyloid PET imaging in posterior cortical atrophy. *Journal of Neurology*, **2015**, 262, 1483-92	3.9	40
99	Neuropsychological Profiles Differ among the Three Variants of Primary Progressive Aphasia. *Journal of the International Neuropsychological Society*, **2015**, 21, 429-35	3.1	50
98	TAR DNA-binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features. *Annals of Neurology*, **2015**, 78, 697-709	9.4	67
97	Dominant frontotemporal dementia mutations in 140 cases of primary progressive aphasia and speech apraxia. *Dementia and Geriatric Cognitive Disorders*, **2015**, 39, 281-6	2.6	26
96	Clinical and neuroimaging biomarkers of amyloid-negative logopenic primary progressive aphasia. *Brain and Language*, **2015**, 142, 45-53	2.9	38
95	Microbleeds in atypical presentations of Alzheimer's disease: a comparison to dementia of the Alzheimer's type. *Journal of Alzheimer's Disease*, **2015**, 45, 1109-17	4.3	12
94	Progressive Apraxia of Speech and Primary Progressive Aphasias **2014**, 213-230		1
93	The pimple sign of progressive supranuclear palsy syndrome. *Parkinsonism and Related Disorders*, **2014**, 20, 180-5	3.6	29

92	Microbleeds in the logopenic variant of primary progressive aphasia. *Alzheimer's and Dementia*, **2014**, 10, 62-6	1.2	9
91	Staging TDP-43 pathology in Alzheimer's disease. *Acta Neuropathologica*, **2014**, 127, 441-50	14.3	199
90	APOE ε4 influences Aβ-amyloid deposition in primary progressive aphasia and speech apraxia. *Alzheimer's and Dementia*, **2014**, 10, 630-6	1.2	25
89	The evolution of primary progressive apraxia of speech. *Brain*, **2014**, 137, 2783-95	11.2	99
88	FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants. *Journal of Neurology*, **2014**, 261, 710-6	5.5	48
87	TDP-43 is a key player in the clinical features associated with Alzheimer's disease. *Acta Neuropathologica*, **2014**, 127, 811-24	14.3	240
86	Improved DTI registration allows voxel-based analysis that outperforms tract-based spatial statistics. *NeuroImage*, **2014**, 94, 65-78	7.9	135
85	Diffusion tensor imaging comparison of progressive supranuclear palsy and corticobasal syndromes. *Parkinsonism and Related Disorders*, **2014**, 20, 493-8	3.6	37
84	Quantitative application of the primary progressive aphasia consensus criteria. *Neurology*, **2014**, 82, 1119-26	8.3	109
83	Nonverbal oral apraxia in primary progressive aphasia and apraxia of speech. *Neurology*, **2014**, 82, 1729-35	8.3	46
82	Progranulin-associated PiB-negative logopenic primary progressive aphasia. *Journal of Neurology*, **2014**, 261, 604-14	5.5	48
81	Ideomotor apraxia in agrammatic and logopenic variants of primary progressive aphasia. *Journal of Neurology*, **2013**, 260, 1594-600	5.5	18
80	Identification of an atypical variant of logopenic progressive aphasia. *Brain and Language*, **2013**, 127, 139-44	2.9	36
79	Modeling trajectories of regional volume loss in progressive supranuclear palsy. *Movement Disorders*, **2013**, 28, 1117-24	7	31
78	Frontal asymmetry in behavioral variant frontotemporal dementia: clinicoimaging and pathogenetic correlates. *Neurobiology of Aging*, **2013**, 34, 636-9	5.6	45
77	Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects?. *NeuroImage: Clinical*, **2013**, 2, 249-57	5.3	35
76	Quantitative neurofibrillary tangle density and brain volumetric MRI analyses in Alzheimer's disease presenting as logopenic progressive aphasia. *Brain and Language*, **2013**, 127, 127-34	2.9	44
75	Aphasia with left occipitotemporal hypometabolism: a novel presentation of posterior cortical atrophy?. *Journal of Clinical Neuroscience*, **2013**, 20, 1237-40	2.2	10

74	Distinct regional anatomic and functional correlates of neurodegenerative apraxia of speech and aphasia: an MRI and FDG-PET study. *Brain and Language*, **2013**, 125, 245-52	2.9	58
73	Corticospinal tract degeneration associated with TDP-43 type C pathology and semantic dementia. *Brain*, **2013**, 136, 455-70	11.2	30
72	Elevated occipital amyloid deposition is associated with widespread cognitive impairment in logopenic progressive aphasia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2013**, 84, 1357-64	5.5	21
71	Syndromes dominated by apraxia of speech show distinct characteristics from agrammatic PPA. *Neurology*, **2013**, 81, 337-45	6.5	114
70	FDG PET and MRI in logopenic primary progressive aphasia versus dementia of the Alzheimer's type. *PLoS ONE*, **2013**, 8, e62471	3.7	75
69	Imaging measures predict progression in progressive supranuclear palsy. *Movement Disorders*, **2012** , 27, 1801-4	7	15
68	Characterization of a family with c9FTD/ALS associated with the GGGGCC repeat expansion in C9ORF72. *Archives of Neurology*, **2012**, 69, 1164-9		16
67	Imaging brain atrophy in progressive supranuclear palsy and corticobasal syndromes: potential for diagnosis and monitoring of disease progression. *Neurodegenerative Disease Management*, **2012**, 2, 589-598	2.8	
66	Recent advances in the imaging of frontotemporal dementia. *Current Neurology and Neuroscience Reports*, **2012**, 12, 715-23	6.6	31
65	Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: determining sample size for treatment trials. *Parkinsonism and Related Disorders*, **2012**, 18, 252-6	3.6	44
64	Right temporal variant frontotemporal dementia with motor neuron disease. *Journal of Clinical Neuroscience*, **2012**, 19, 85-91	2.2	13
63	Characterizing a neurodegenerative syndrome: primary progressive apraxia of speech. *Brain*, **2012**, 135, 1522-36	11.2	253
62	Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. *Lancet Neurology, The*, **2012**, 11, 868-77	24.1	254
61	Neuroimaging in frontotemporal lobar degeneration--predicting molecular pathology. *Nature Reviews Neurology*, **2012**, 8, 131-42	15	54
60	Primary lateral sclerosis as progressive supranuclear palsy: diagnosis by diffusion tensor imaging. *Movement Disorders*, **2012**, 27, 903-6	7	10
59	Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. *Brain*, **2012**, 135, 794-806	11.2	306
58	Comparison of imaging biomarkers in the Alzheimer Disease Neuroimaging Initiative and the Mayo Clinic Study of Aging. *Archives of Neurology*, **2012**, 69, 614-22		53
57	Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. *Brain*, **2012**, 135, 765-83	11.2	277

56	Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND. *NeuroImage*, **2011**, 55, 522-31	7.9	74
55	Focal brain atrophy in gastric bypass patients with cognitive complaints. *Journal of Clinical Neuroscience*, **2011**, 18, 1671-6	2.2	8
54	Disrupted thalamocortical connectivity in PSP: a resting-state fMRI, DTI, and VBM study. *Parkinsonism and Related Disorders*, **2011**, 17, 599-605	3.6	125
53	Temporoparietal atrophy: a marker of AD pathology independent of clinical diagnosis. *Neurobiology of Aging*, **2011**, 32, 1531-41	5.6	77
52	Corticobasal degeneration: a pathologically distinct 4R tauopathy. *Nature Reviews Neurology*, **2011**, 7, 263-72	15	167
51	Imaging signatures of molecular pathology in behavioral variant frontotemporal dementia. *Journal of Molecular Neuroscience*, **2011**, 45, 372-8	3.3	49
50	Gray matter correlates of behavioral severity in progressive supranuclear palsy. *Movement Disorders*, **2011**, 26, 493-8	7	37
49	Predicting functional decline in behavioural variant frontotemporal dementia. *Brain*, **2011**, 134, 432-48	11.2	35
48	Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. *Journal of Neurology, Neurosurgery and Psychiatry*, **2011**, 82, 196-203	5.5	146
47	Assessing subtle structural changes in Alzheimer's disease patients. *Methods in Molecular Biology*, **2011**, 711, 535-50	1.4	2
46	Clinical correlates of white matter tract degeneration in progressive supranuclear palsy. *Archives of Neurology*, **2011**, 68, 753-60		90
45	Fluorodeoxyglucose F18 positron emission tomography in progressive apraxia of speech and primary progressive aphasia variants. *Archives of Neurology*, **2010**, 67, 596-605		81
44	Symmetric corticobasal degeneration (S-CBD). *Parkinsonism and Related Disorders*, **2010**, 16, 208-14	3.6	46
43	The protective role of brain size in Alzheimer's disease. *Expert Review of Neurotherapeutics*, **2010**, 10, 1799-801	4.3	9
42	Progression of atrophy in Alzheimer's disease and related disorders. *Neurotoxicity Research*, **2010**, 18, 339-46	4.3	46
41	Anatomical differences between CBS-corticobasal degeneration and CBS-Alzheimer's disease. *Movement Disorders*, **2010**, 25, 1246-52	7	58
40	MRI correlates of protein deposition and disease severity in postmortem frontotemporal lobar degeneration. *Neurodegenerative Diseases*, **2009**, 6, 106-17	2.3	43
39	The clinical profile of right temporal lobe atrophy. *Brain*, **2009**, 132, 1287-98	11.2	220

38	Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. *Brain*, **2009**, 132, 2932-46	11.2	223
37	Voxel-based morphometry: an automated technique for assessing structural changes in the brain. *Journal of Neuroscience*, **2009**, 29, 9661-4	6.6	204
36	Voxel-based morphometry in autopsy proven PSP and CBD. *Neurobiology of Aging*, **2008**, 29, 280-9	5.6	200
35	Anatomic correlates of stereotypies in frontotemporal lobar degeneration. *Neurobiology of Aging*, **2008**, 29, 1859-63	5.6	37
34	Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies. *NeuroImage*, **2008**, 39, 1186-97	7.9	342
33	Rates of brain atrophy over time in autopsy-proven frontotemporal dementia and Alzheimer disease. *NeuroImage*, **2008**, 39, 1034-40	7.9	46
32	Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. *NeuroImage*, **2008**, 42, 559-67	7.9	137
31	Longitudinal imaging: change and causality. *Current Opinion in Neurology*, **2008**, 21, 410-6	7.1	10
30	Volumetric MRI and cognitive measures in Alzheimer disease : comparison of markers of progression. *Journal of Neurology*, **2008**, 255, 567-74	5.5	103
29	The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. *Journal of Magnetic Resonance Imaging*, **2008**, 27, 685-91	5.6	1797
28	Beta-amyloid burden is not associated with rates of brain atrophy. *Annals of Neurology*, **2008**, 63, 204-12	9.4	162
27	Neuroimaging in dementia. *Neurologic Clinics*, **2007**, 25, 843-57, viii	4.5	16
26	Neuroimaging in Dementia. *PET Clinics*, **2007**, 2, 15-24	2.2	1
25	Rates of cerebral atrophy differ in different degenerative pathologies. *Brain*, **2007**, 130, 1148-58	11.2	125
24	Patterns of atrophy differ among specific subtypes of mild cognitive impairment. *Archives of Neurology*, **2007**, 64, 1130-8		164
23	Voxel-based morphometry in frontotemporal lobar degeneration with ubiquitin-positive inclusions with and without progranulin mutations. *Archives of Neurology*, **2007**, 64, 371-6		79
22	NEUROIMAGING IN DEMENTIA. *CONTINUUM Lifelong Learning in Neurology*, **2007**, 13, 180-203	3	1
21	Imaging correlates of posterior cortical atrophy. *Neurobiology of Aging*, **2007**, 28, 1051-61	5.6	137

20	VBM signatures of abnormal eating behaviours in frontotemporal lobar degeneration. *NeuroImage*, **2007**, 35, 207-13	7.9	111
19	Voxel-based morphometry and its application to movement disorders. *Parkinsonism and Related Disorders*, **2007**, 13 Suppl 3, S406-16	3.6	26
18	Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. *Brain*, **2007**, 130, 708-19	11.2	238
17	3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. *Brain*, **2007**, 130, 1777-86	11.2	462
16	Rates of cerebral atrophy in autopsy-confirmed progressive supranuclear palsy. *Annals of Neurology* , **2006**, 59, 200-3	9.4	30
15	Measurements of the amygdala and hippocampus in pathologically confirmed Alzheimer disease and frontotemporal lobar degeneration. *Archives of Neurology*, **2006**, 63, 1434-9		120
14	Patterns of atrophy in pathologically confirmed FTLD with and without motor neuron degeneration. *Neurology*, **2006**, 66, 102-4	6.5	346
13	Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. *Brain*, **2006**, 129, 1385-98	11.2	529
12	Visual hallucinations in posterior cortical atrophy. *Archives of Neurology*, **2006**, 63, 1427-32		52
11	Frontotemporal lobar degeneration without lobar atrophy. *Archives of Neurology*, **2006**, 63, 1632-8		48
10	Comparisons between Alzheimer disease, frontotemporal lobar degeneration, and normal aging with brain mapping. *Topics in Magnetic Resonance Imaging*, **2005**, 16, 409-25	2.3	65
9	A volumetric magnetic resonance imaging study of the amygdala in frontotemporal lobar degeneration and Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders*, **2005**, 20, 238-44	2.6	33
8	Magnetic resonance imaging signatures of tissue pathology in frontotemporal dementia. *Archives of Neurology*, **2005**, 62, 1402-8		120
7	Longitudinal patterns of regional change on volumetric MRI in frontotemporal lobar degeneration. *Dementia and Geriatric Cognitive Disorders*, **2004**, 17, 307-10	2.6	66
6	Voxel-based morphometry in tau-positive and tau-negative frontotemporal lobar degenerations. *Neurodegenerative Diseases*, **2004**, 1, 225-30	2.3	20
5	Using nine degrees-of-freedom registration to correct for changes in voxel size in serial MRI studies. *Magnetic Resonance Imaging*, **2004**, 22, 993-9	3.3	13
4	Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study. *Lancet, The*, **2003**, 362, 1121-2	40	168
3	A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging. *Archives of Neurology*, **2003**, 60, 989-94		585

2	Patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease. *Annals of Neurology*, **2001**, 49, 433-442	9.4	561
1	Tauopathies147-166		1